3α-Aminocholestane

CAS No. 2206-20-4

3α-Aminocholestane( —— )

Catalog No. M33248 CAS No. 2206-20-4

3α-Aminocholestane (5α-Cholestan-3α-amine) is a potent inhibitor of inositol-5'-phosphatase 1 (SHIP1) containing the SH2 structural domain (IC50 : 2.5 μM) for research and immune-related diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 74 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    3α-Aminocholestane
  • Note
    Research use only, not for human use.
  • Brief Description
    3α-Aminocholestane (5α-Cholestan-3α-amine) is a potent inhibitor of inositol-5'-phosphatase 1 (SHIP1) containing the SH2 structural domain (IC50 : 2.5 μM) for research and immune-related diseases.
  • Description
    3α-Aminocholestane is a selective SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) inhibitor with an IC50 of ~2.5 μM.
  • In Vitro
    OPM2 cell viability is effectively reduced by 3α-Aminocholestane (3AC) treatment. RPMI8226 and U266 cells show significantly less sensitivity to 3α-Aminocholestane treatment when compare with OPM2 cells, although viability is decreased significantly at concentrations of ≥12.5 μM. Treatment with 3α-Aminocholestane for 36 h severely reduces the percentage of cells in the S phase, which is accompanied by an increase of cells in the G2/M phase. In contrast, in the less proliferative RPMI8226 and U266 cells, cell cycle progression is blocked in the G0/G1 phase upon 3α-Aminocholestane treatment, in conjunction with a reduced percentage of cells undergoing the S phase.
  • In Vivo
    It is found that 3α-Aminocholestane (3AC) results in reduced multiple myeloma (MM) growth in vivo, as determined by quantitation of free human Igλ light chain in the plasma after OPM2 challenge. In addition, reduced numbers of circulating OPM2 cells, as determined by human HLA-ABC staining, is observed in peripheral blood from 3α-Aminocholestane-treated mice compare with vehicle controls. Most importantly, 3α-Aminocholestane treatment results in significantly enhanced survival of mice after tumor challenge. In 3α-Aminocholestane-treated mice that resist treatment, it is found that MM tumors exhibit an upregulation of SHIP2, reminiscent of in vitro treatment of OPM2 cells and suggesting that SHIP1 inhibition may select for tumor cells with increased SHIP2 expression.
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Phosphatase
  • Recptor
    Phosphatase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2206-20-4
  • Formula Weight
    387.68
  • Molecular Formula
    C27H49N
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?Ethanol : 50 mg/mL (128.97 mM; Ultrasonic) DMSO : < 1 mg/mL (insoluble or slightly soluble)
  • SMILES
    [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](N)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chen Z, et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015 May 21;521(7552):357-61.
molnova catalog
related products
  • NSC 95397

    NSC 95397 is a ?potent inhibitor of Cdc25 dual specificity phosphatase(Ki of 32 96 and 40 nM for Cdc25A Cdc25B and Cdc25C respectively).

  • KLH45

    KLH45 is an effective and selective inhibitor of Spastic Paraplegia-Related Triglyceride Hydrolase DDHD2(IC50 = 1.3 nM).

  • TNO155

    TNO155 is a protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11) inhibitor(IC50 : 0.011 μM),with potential antineoplastic activity.